The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition
Luca Mologni(Azienda Ospedaliera San Gerardo), Carlo Gambacorti‐Passerini(Azienda Ospedaliera San Gerardo)
Cited by 13
Related Papers
Clinical and biological implications of driver mutations in myelodysplastic syndromes
|Blood|2013|1.8k
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL
|Blood|2016|329
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317